{"id":"NCT03350542","sponsor":"Boston Scientific Corporation","briefTitle":"A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)","officialTitle":"EVOLVE 48: A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of the SYNERGY 48 mm Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-12","primaryCompletion":"2020-01-16","completion":"2021-01-08","firstPosted":"2017-11-22","resultsPosted":"2021-02-05","lastUpdate":"2021-05-14"},"enrollment":100,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Coronary Artery Disease"],"interventions":[{"type":"DEVICE","name":"SYNERGY 48 mm","otherNames":[]}],"arms":[{"label":"SYNERGY 48 mm","type":"EXPERIMENTAL"}],"summary":"EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) \\> 34 mm and ≤ 44 mm in length (by visual estimate) in native coronary arteries ≥2.5 mm to ≤4.0 mm in diameter (by visual estimate).","primaryOutcome":{"measure":"Target Lesion Failure Rate at 12-months","timeFrame":"12-month","effectByArm":[{"arm":"SYNERGY 48 mm","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":21},"locations":{"siteCount":15,"countries":["United States","Latvia","New Zealand","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":100},"commonTop":["Angina unstable","Blood creatine phosphokinase MB increased","Coronary artery occlusion","Electrocardiogram T wave abnormal"]}}